We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Bluebird Bio (BLUE - Free Report) shares soared 15.7% in the last trading session to close at $6.86. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.3% gain over the past four weeks.
Shares surged as investors are impressed by bluebird’s recent pipeline progress. The company recently received accelerated FDA approval for its gene therapy candidate, Syskona (eli-cel) for cerebral adrenoleukodystrophy (CALD). FDA also lifted the clinical hold on the eli-cel clinical development program. Bluebird’s other gene therapy candidate Zynteglo (beti-cel) for beta-thalassemia was approved by the FDA in August.
This biotechnology company is expected to post quarterly loss of $1.27 per share in its upcoming report, which represents a year-over-year change of +56.7%. Revenues are expected to be $2.15 million, down 90.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Bluebird, the consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BLUE going forward to see if this recent jump can turn into more strength down the road.
Bluebird belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Insmed (INSM - Free Report) , closed the last trading session 1.5% lower at $23.78. Over the past month, INSM has returned -5.3%.
For Insmed, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.87. This represents a change of +9.4% from what the company reported a year ago. Insmed currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?
Bluebird Bio (BLUE - Free Report) shares soared 15.7% in the last trading session to close at $6.86. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.3% gain over the past four weeks.
Shares surged as investors are impressed by bluebird’s recent pipeline progress. The company recently received accelerated FDA approval for its gene therapy candidate, Syskona (eli-cel) for cerebral adrenoleukodystrophy (CALD). FDA also lifted the clinical hold on the eli-cel clinical development program. Bluebird’s other gene therapy candidate Zynteglo (beti-cel) for beta-thalassemia was approved by the FDA in August.
This biotechnology company is expected to post quarterly loss of $1.27 per share in its upcoming report, which represents a year-over-year change of +56.7%. Revenues are expected to be $2.15 million, down 90.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Bluebird, the consensus EPS estimate for the quarter has been revised 4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on BLUE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Bluebird belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Insmed (INSM - Free Report) , closed the last trading session 1.5% lower at $23.78. Over the past month, INSM has returned -5.3%.
For Insmed, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.87. This represents a change of +9.4% from what the company reported a year ago. Insmed currently has a Zacks Rank of #3 (Hold).